Intellia Therapeutics
NTLA
11.71
-0.66
-5.34%
Intellia Therapeutics
US · NTLA
#2899 by market cap
Listed 2016
11.71
-0.66
-5.34%
Live - 5344 symbols - heartbeat 222s ago
· 2026-10-08 08:30
Pre-market
11.66
-0.43%
After-hours
11.81
+0.85%
Overnight
11.68
-0.26%
- Market cap
- 1.64B
- P/E (TTM)i
- -3.51
- P/Bi
- 2.25
- EPSi
- -3.81
- Div yieldi
- 0.00%
- 52W posi
- 19%
Reader sentiment
Are you bullish or bearish on NTLA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.42, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.92% YoY
Margins
- Operating margin
- -651.67%
- Net margin
- -609.85%
Key ratios & quality
- Altman Z-Scorei
- 0.42
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.43M | 43.10M | 57.99M | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 32.19M | 41.06M | 44.17M | 71.10M | 90.31M | 116.50M | 125.83M | 119.80M |
| Research & development | 89.12M | 108.41M | 150.41M | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Operating profit | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M | -440.99M |
| Pretax profit | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -412.69M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -85.34M | -99.53M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -412.69M |
| Basic EPS | -2 | -2 | -2 | -4 | -6 | -5 | -5 | -4 |
| Diluted EPS | -1.98 | -2.11 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 16.63M | 14.25M | 13.78M | 23.02M | 15.05M | 7.66M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 29.01M | 27.21M | 30.51M | 33.08M | 34.84M | 37.82M |
| Research & development | 108.43M | 97.04M | 94.75M | 88.65M | 80.74M | 82.60M |
| Operating profit | -120.81M | -110.00M | -111.48M | -98.71M | -100.53M | -112.76M |
| Pretax profit | -114.33M | -101.26M | -101.32M | -95.79M | -96.23M | -106.63M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -114.33M | -101.26M | -101.32M | -95.79M | -96.23M | -106.63M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.10 | -0.98 | -0.92 | -0.83 | -0.81 | -0.80 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 324.98M | 289.48M | 616.52M | 769.30M | 1.22B | 998.33M | 639.86M | 527.71M |
| Cash & ST investments | 314.06M | 279.73M | 597.37M | 748.69M | 1.19B | 912.22M | 601.52M | 449.88M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 347.32M | 334.28M | 676.32M | 1.29B | 1.52B | 1.30B | 1.19B | 842.13M |
| Total current liabilities | 40.57M | 35.63M | 64.25M | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M |
| Short-term debt | -- | 5.75M | 5.70M | 9.11M | 16.69M | 18.60M | 20.25M | 26.48M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 69,395,000.00 | 64,399,000.00 | 149,250,000.00 | 254,220,000.00 | 284,530,000.00 | 250,808,000.00 | 319,059,000.00 | 170,733,000.00 |
| Total equity | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M |
| Retained earnings | -201.03M | -300.88M | -435.11M | -703.00M | -1.18B | -1.66B | -2.18B | -2.59B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 551.39M | 495.95M | 581.94M | 527.71M | 466.45M | 527.83M |
| Cash & ST investments | 503.75M | 459.65M | 511.04M | 449.88M | 375.99M | 437.76M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 986.16M | 898.89M | 925.28M | 842.13M | 758.78M | 857.16M |
| Total current liabilities | 112.59M | 95.50M | 93.73M | 103.88M | 76.45M | 79.39M |
| Short-term debt | 38.76M | 26.99M | 27.38M | 26.48M | 19.10M | 23.34M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 206,244,000.00 | 183,639,000.00 | 176,853,000.00 | 170,733,000.00 | 137,840,000.00 | 129,458,000.00 |
| Total equity | 779.92M | 715.26M | 748.42M | 671.39M | 620.94M | 727.71M |
| Retained earnings | -2.29B | -2.39B | -2.49B | -2.59B | -2.69B | -2.79B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -61.26M | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M | -348.88M | -394.74M |
| Depreciation & amortization | 4.46M | 5.59M | 6.31M | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Free cash flow | -67.62M | -110.03M | -53.50M | -237.79M | -391.68M | -408.07M | -354.66M | -395.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 28.55M | 72.26M | 358.65M | 693.57M | 565.79M | 119.80M | 176.90M | 128.18M |
| Ending cash balance | 58.86M | 57.23M | 164.61M | 125.49M | 535.46M | 240.35M | 202.79M | 167.57M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -148.93M | -99.62M | -76.90M | -69.29M | -117.35M | -83.11M |
| Depreciation & amortization | 2.50M | 2.47M | 4.94M | 6.02M | 2.20M | 2.08M |
| Free cash flow | -149.67M | -99.86M | -76.93M | -69.41M | -117.43M | -84.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 13.42M | 114.76M | 0 | 33.57M | 194.58M |
| Ending cash balance | 148.19M | 170.13M | 207.34M | 167.57M | 150.10M | 121.53M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -29.50 | -36.34 | -33.69 | -34.18 | -41.67 | -42.10 | -54.00 | -53.48 |
| ROA %i | -23.59 | -29.21 | -26.56 | -27.19 | -33.70 | -34.11 | -41.66 | -40.60 |
| ROIC %i | -31.41 | -36.39 | -31.96 | -32.03 | -38.92 | -41.95 | -50.44 | -47.85 |
| 5-year avg ROE %i | -- | -- | -31.91 | -32.04 | -35.08 | -37.60 | -41.13 | -45.09 |
| EBIT margin %i | -298.58 | -246.78 | -235.51 | -810.37 | -879.04 | -1,420.51 | -923.10 | -651.67 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.01 | 8.12 | 9.59 | 6.11 | 9.61 | 8.67 | 5.77 | 5.08 |
| Quick ratioi | 7.93 | 7.98 | 9.33 | 5.97 | 9.45 | 8.23 | 5.50 | 4.42 |
| Debt / assetsi | 0.00 | 5.50 | 5.81 | 5.72 | 8.60 | 8.87 | 17.65 | 11.08 |
| LT debt / equityi | -- | 4.68 | 6.38 | 6.24 | 9.23 | 9.21 | 21.78 | 9.96 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 71.40 | 37.78 | 30.46 | 2.79 | 6.54 | -14.48 | 20.53 | 9.09 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -57.92 | -56.95 | -52.11 | -53.48 | -56.34 | -55.44 |
| ROA %i | -46.84 | -45.94 | -42.49 | -40.60 | -45.23 | -45.55 |
| ROIC %i | -55.68 | -54.76 | -50.16 | -47.85 | -52.53 | -52.40 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,187.36 | -968.69 | -832.16 | -651.67 | -636.56 | -711.66 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.90 | 5.19 | 6.21 | 5.08 | 6.10 | 6.65 |
| Quick ratioi | 4.57 | 4.93 | 5.57 | 4.42 | 5.04 | 5.61 |
| Debt / assetsi | 12.09 | 11.41 | 10.59 | 11.08 | 10.61 | 8.56 |
| LT debt / equityi | 10.32 | 10.57 | 9.43 | 9.96 | 9.89 | 6.88 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
The development of gene editing-based therapies100.00%
Quote time 2026-10-08 08:30:29 · For reference only, not investment advice and not tailored to your situation.